CD4 and neoplasm: Using tumour biopsies obtained prior to nivolumab treatment, tumour PD-L1 expression and CD8+ tumour-infiltrating immune cell expression were assessed, as well as stromal PD-1+, PD-L1+, CD3+, CD4+ and CD8+ immune cell expression.